Literature DB >> 2433537

Overview of cardiac inotropic mechanisms.

P K Siegl.   

Abstract

Cardiac inotropic mechanisms have been studied by basic and clinical scientists for many years. New knowledge and insights into cardiac muscle physiology and pharmacology, as well as novel drugs for the treatment of cardiac diseases, have resulted from these research efforts. This article reviews known inotropic mechanisms (both pharmacological and nonpharmacological) and provides background for more complete discussions of novel inotropic mechanisms found in this supplement issue.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2433537

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

1.  In vivo anaphylaxis in the rat: effects of phosphodiesterase inhibitors.

Authors:  M J Post; J D te Biesebeek; J Wemer; H H van Rooij; A J Porsius
Journal:  Agents Actions       Date:  1989-01

2.  Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.

Authors:  D Brunkhorst; H v der Leyen; W Meyer; R Nigbur; C Schmidt-Schumacher; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

3.  Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts.

Authors:  T Bethke; D Brunkhorst; H von der Leyen; W Meyer; R Nigbur; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

4.  Amiloride analogues induce responses in isolated rat cardiovascular tissues by inhibition of Na+/Ca2+ exchange.

Authors:  L Brown; E J Cragoe; K C Abel; S W Manley; J R Bourke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-08       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.